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Streptokinase-activated fibrinolysis of platelet-poor citrated 
dog plasma was studied by thrombelastography before, during, and 
after administration of choline. Plasma samples were tested in 
several clot-lysis systems containing: 1) human plasma or
euglobulins for providing proactivator and needed clotting factors 
for hemophilic plasma; 2) varying concentrations of streptokinase; 
3) calcium chloride.
Three hemophilic (Factor VUI-deficient) and four normal 
dogs were treated with choline for periods of 3 - 15 days during 
a 10-month study. The choline (as dihydrogen citrate), administered 
perorally at 5 times normal dietary level, significantly increased 
fibrinolysis times within 24 hours in all of the dogs tested.
Dosage with citric acid, for control purposes, did not cause 
prolongation of fibrinolysis.
Explanation of previously reported beneficial effects of 
choline-containing peanut extracts in hemophilia is discussed in 
terms of the effect on fibrinolysis reported here. It appears 
that high choline dosage should permit a more effective hemostatic 
clot in hemophilia. Observations on bleeding episodes of the 
hemophilic dogs used in this study give further support for the 
antifibrinolytic effect of high choline dosage.
vi
INTRODUCTION
Hemophilia, in addition to its occurrence in humans, has been 
reported in horses (Sanger, Mairs, and Tropp, 1964), swine (Cornell 
and Merkner, 1964) and in dogs (Field, Richard, and Hutt, 1946; 
Mustard et al., 1960; Mustard et al., 1962; Brock et al., 1963; 
Didisheim and Bunting, 1964; Kaneko, Cordy, and Carlson, 1967). 
Clinical treatment and establishment of colonies for hemophilic 
dogs have been described (Graham et al., 1949; Sharp and Dike, 1964; 
Brock et al., 1963; Bird et al., 1964). The latter 2 reports were 
on the colony at Oklahoma State University, Stillwater, from which 
the dogs used in this research were obtained. Brinkhous and 
Graham (1950) described hemophilia in the female dog and Parks et al.
(1964) recount laboratory detection of female carriers of canine 
hemophilia, in the colony at Chapel Hill, North Carolina, described 
by Graham et al. (1949). Canine hemophilia has been shown to have 
many similarities to hemophilia in man and has also been shown to 
be a sex-linked inherited deficiency of factor VIII activity in some 
of the dogs, as those in the colonies listed above at Chapel Hill 
and Oklahoma. Dogs from the Oklahoma colony formed the nucleus of 
the colony established at Louisiana State University and were used 
in the present study for testing the possible beneficial effect 
that choline may have on their bleeding tendency.
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The idea of the use of choline as an aid in controlling mild 
bleeding episodes in hemophilia had its origin in the work by 
Boudreaux and Frampton (1960). Boudreaux, a factor VIII-activity 
deficient hemophiliac, observed that the tenderness of an acute 
hemarthritic knee seemed to subside after the ingestion of roasted 
peanuts. A series of experimental investigations followed to try 
to explain how peanuts could provide clinical relief from bleeding. 
Since no change in the coagulability of the blood could be found 
(Schmutzler, 1961) other explanations for the possible beneficial 
effect of peanuts were postulated. Ethanolic extracts of 
defatted peanuts (Boudreaux et al. 1960, Frampton et al. 1966) 
were further separated by solvent separation and by chromatography 
into fractions, one of which was reported to shorten bleeding time 
in hamsters. Astrup et al. (1960) suggested that the possible 
effect of peanuts is the shifting of the hemostatic balance in the 
organism due to pro tease inhibitors present. Pro tease inhibitors 
had been known to be present in peanuts since Borchers' report in 
1947. Astrup et al. suggested that, acting as antifibrinolytic 
agents, such inhibitors could delay resolution of small fibrin 
deposits and thus improve hemostasis. Van Creveld and Mochtar (1961) 
as well as Moers and den Ottolander (1961) demonstrated shortened 
euglobulin clot lysis times in hemophilic patients consuming 
peanut products. Nilsson (1960) reported an antifibrinolytic 
effect using streptokinase and plasma from hemophilic patients who 
had ingested roasted peanuts. Schmutzler (1961) found a small amount
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of antifibrinolytic activity in ethanol extract from peanuts.
Brahman, Sj^lin, and Astrup (1962) reported a decrease in 
spontaneous fibrinolytic activity with peanut administration.
Bisordi (1964) reported clinical benefit in hemophiliacs treated 
with peanut flour. A potent antifibrinolytic substance extracted 
from peanut skins was claimed by Sepelak (1963) to promote hemostasis 
in hemophilia and other hemorrhagic states. Novak (1966) indicated 
that peanut extract injected intravenously inhibited fibrinolysis 
in dogs.
Frampton et al. (1966) processed peanuts through an extended 
series of extractions and chromatographic separations in an effort 
to isolate the active hemostatic material. Jackson, Owen, and 
Boudreaux (1966) on the basis of pharmacological and chemical studies 
on fractions derived from alcoholic extracts concluded that 
clinical improvement afforded hemophiliacs by consumption of peanuts 
or its extracts may be attributable to choline. Boudreaux is 
apparently controlling his bleeding tendency by using 8 grams 
daily of choline dihydrogen citrate.
A known inhibitor of fibrinolysis, epsilon-aminocaproic acid 
(EACA) has been used therapeutically in normal and hemophilic 
cases (Reid et al., 1964; Mainwaring and Keidan, 1965; Reid et al., 
1965; Nilsson, 1966; Reid, Hodge, and Cerutti, 1967). An even 
more powerful inhibitor, trans-4-amino-methylcyclohexane-l-carboxylic 
acid (AMCHA) is currently claiming the interest of workers in this 
field. Results of an in vivo study using dogs have recently been 
published (Celander and Celander, 1968).
Although drawing general conclusions from experimental animals 
is difficult due to the large quantitative and qualitative dif­
ferences between species (Astrup, 1969), testing the fibrinolytic 
inhibition of choline on hemophilic dogs seems worthwhile. Byshevsky 
(1965) exhibited inhibition of fibrinolysis in dogs with intravenous 
injections of choline. The purposes of my research was to test the 
antifibrinolytic effect of choline administered perorally to both 
hemophilic and normal dogs and to observe possible clinical benefit 
to the hemophilic dogs.
Thrombelastography (Hartert, 1951) was the choice for study 
of both the formation and dissolution of the clot formed from dogs 
administered choline. This method has been used to study hemophilia 
(de Nicola and Mazzetti, 1956; de Nicola, 1957a; de Nicola, 1957b) 
and shown to be a good system for studying fibrinolysis (Von Kaulla 
and Weiner, 1955; Von Kaulla, 1957; de Nicola and Mazzetti, 1957;
Von Kaulla and Schultz, 1958; Astrup and Egeblad, 1965). The effect 
of EACA and the trypsin inhibitor in peanuts on fibrinolysis in vitro 
were demonstrated with thrombelastography (Egeblad, 1966, 1967a and 
1967b). The role of fibrinolytic inhibitors on hemophilia was 
tested by Reid et al. (1965) also using thrombelastography. They
* * ’ • '.kV
found that EACA had a normalizing effect On the hemophilic 
thrombelastogram.
Normal values for the thrombelastograms in dogs were reported 
by Popisil (1966) but normal values for thrombelastograms of 
streptokinase-activated fibrinolysis in the normal or hemophilic dog 
could not be found in the literature. Studies on fibrinolysis in
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the dog such as Holemans1 study (1965) and on the effect of AMCHA 
on fibrinolysis by Celander and Celander (1968) were helpful. Very 
high platelet numbers may have either a fibrinolytic (Holemans and 
Gross, 1961a and 1961b) or an antifibrinolytic (Johnson, 1953 and 
Stefanini, 1956) action. Only small numbers of platelets were 
used in the present study, minimizing the effect of platelets on 
fibrinolysis.
Streptokinase-activated fibrinolysis by means of thromb­
elastography (de Nicola, 1957; Astrup and Egeblad, 1965) was the 
chosen method for measuring fibrinolysis after choline treatment 
of the dogs. Reviews (Sherry, and Alkjaersig 1958; Sherry,
Fletcher, and Alkjaersig, 1959; Sherry, 1968; Astrup, 1969) 
suggest that SK-activated fibrinolysis is a useful system for 
measuring inhibitors of fibrinolysis. By using thrombelastography, 
other parameters of the clot, such as clot firmness (Weiner and 
Weisberg, 1957), could be observed simultaneously for differences 
that might occur due to choline.
It was kept in mind that if choline has a favorable influence 
in hemophilia it might have an unfavorable one in normal animals.
In studies done on rats primarily to test the effect of butter and 
c o m  oil on the lytic phase of thrombelastograms, but which employed 
diets with high choline levels, pathological conditions associated 
with prolonged fibrinolysis times developed (Tillman et al., 1960; 
Lee et al., 1962; Kim et al., 1963; Lee, Kim, and Sherman, 1963;
Kim et al., 1964; Kim, Lee, and Thomas, 1965; Nam et al., 1965).
Many suggestions are brought forth to explain the above phenomenon.
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Beta-lipoproteins have been shown to have antifibrinolytic activity 
(Skrzydlewski and Niewiarowski, 1966; Riding and Ellis, 1964) and 
are elevated in atherosclerotic sera (Sarkar, 1961). Perhaps 
choline is associated with these two phenomena. But again one must 
be extremely careful in generalizing from one animal system to 
another.
The measurement of the beneficial effects and mechanism of 
action were the main aims of this research. If choline can be 
shown to be hemostatic in hemophilic dogs, then further studies 
using human subjects would be in order.
MATERIALS AND METHODS
General design and plan of work. Streptokinase (SK) -activated
I
fibrinolysis was studied by thrombelastography in 5 normal and 3 hemo­
philic dogs. Blood samples were collected when the only source of 
choline was that provided by the diet and also while extra choline was 
given perorally. Six separate periods of choline treatment (3 - 15 
days' duration) were used during the 10-month study. In 4 of the 
periods, 6 dogs were treated; in 1 case, 1 dog only; in the remaining 
period, 2 dogs. For choline dosage, commercially available tablets 
containing 600 mg choline dihydrogen citrate were used. Four times 
daily, each dog was made to swallow a tablet or a half-tablet, depending 
on body weight and desired dose. In certain test periods, doses of 
300 mg choline citrate per 17 - 20 lb body weight were given (1200 mg/ 
day for the adult dogs). In other treatments, the dosage was twice 
this amount.
For control purposes, 2 test periods were provided during which 
time the dogs were given citric acid 4 times daily, in quantities 
equivalent to those of the citrate provided in the tests with choline 
dihydrogen citrate. Also, for some comparison of the effect of choline 
on SK-activated fibrinolysis with that produced by a better-known 
inhibitor of fibrinolysis, two short experiments were run with EACA.
In each of these, 2 dogs were given, perorally, single doses of
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0.34 mg/kg body weight. Blood samples were taken in one experiment 
3 hours after the EACA; in the other experiment, after 7 hours.
An essential part of this study was investigation of the 
composition of clotting-lysis mixtures suitable for thrombe­
lastographic studies with hemophilic dog plasma. For promptness 
in clotting of hemophilic plasma and achievement of a satisfactory 
maximum amplitude, inclusion of the deficient clotting factor was 
essential. For SK-activation of the fibrinolytic system of the 
dog, a source of proactivator from human plasma was required.
Dogs; source; status with regard to hemophilia; maintenance.
The 8 dogs used in this work were members of an inbred colony of 
beagles. Three were originally from the Stillwater, Oklahoma colony 
of the School of Veterinary Medicine, Oklahoma State University; the 
remaining 5 were born in the newly established LSU colony.
Information on the individual animals is given below:
G-3, hemophilic $, obtained as adult, Nov. '67
G-4, hemophilic cf, obtained as adult, Nov. '67




K-9, normal cf, born at LSU, Jan. '69, from mating of T-4 and G-4
A-l, hemophilic cf, born at LSU, Sept. '68, from mating of G-3
and G-4
The adult beagles weighed 17-20 pounds. Three of the younger 
dogs weighed about half this amount when they were first used in
normal cf's, born at LSU, Jan. '68, from mating of T-4 
(carrier obtained from Stillwater) and G-4
9
experimental work; when they were next studied, they had reached adult 
weight.
The hemophilic or normal states of the dogs furnished by 
Oklahoma State University and the dogs born in the LSU colony were 
verified by tests conducted in this laboratory. The dogs with bleeding 
disorders were shown to have classical canine hemophilia; i.e., 
deficient Factor VIII-activity, as indicated by the following tests: 
Lee-White clotting time, prothrombin time, partial thromboplastin time, 
and thromboplastin generation time. Results from thrombelastography 
of whole blood (following procedures according to Marchal, Leroux, and 
Samana, 1963) supported diagnoses of clotting defect (Fig. 1).
The dogs were housed in the LSU Canine Hemophilia Laboratory, a 
small air-conditioned building used exclusively for these studies.
They were caged individually in the main kennel room, and each dog 
had its own outside runway (in an adjoining semi-enclosed area suitably 
protected against weather and insects). The animals were regularly 
attended and fed twice daily. Each adult dog received 40g ez/d 
Prescription Diet® and 160g f/d Prescription Diet® (Mark Morris 
Associates, Inc., Topeka, Kansas) per day. The quantity of ration 
described above provided 220 mg choline.
Bleeding procedure; preparation of citrated samples. The dogs 
were bled immediately after the morning feeding to avoid lipemia and 
shift of fluid from the blood into the digestive tract. The dogs 
were less excitable and easier to handle for venipuncture after feeding. 
Three to five ml of blood was carefully drawn from the jugular vein 




Fig. 1. 'Thrombelas tograms of whole blood from hemophilic dog (G-3) and normal dog (V-l).
stainless steel needle. When the jugular vein was not entered with, 
the first puncture through the skin, then the needle was replaced with 
a new one and the opposite vein used, minimizing tissue fluid contamin­
ation. Blood was withdrawn smoothly, at a rate of about 0.5 ml/sec.
The needle was removed from the syringe and blood was dispensed into 
a siliconized calibrated test tube (12 mm diameter) containing the 
proper volume of ice-cold 3.8% sodium citrate solution required for 
a dilution of 9 parts blood with 1 part citrate solution. Blood 
remaining in the syringe was used for microhematocrit and some whole 
biood platelet counts. All citrated blood samples were kept in an 
ice bath until they were given special processing or directly used 
in tests, and every effort was made to avoid delay in the work. No 
samples were used that were more than 4 hours old.
Platelet-poor plasma for Thrombelastographic studies. Citrated 
blood samples were centrifuged at 3000 rpm (1500 g) for 10 min, using 
a Servall RC-2 centrifuge equipped with a HB-4 head and set for 4° C. 
Each plasma sample was promptly transferred by pipette into a cold 
test tube and kept in an ice bath. All glassware used in handling 
of plasma was siliconized. Counts were made to validate consideration 
of the plasma as "platelet-poor." With almost 200 samples, platelet 
number was not higher than 12,000/mm in 85% of the cases; slightly
qmore than half of the counts were in the range of 3,000-7,000/mm 
(Fig. 2).
Platelet counts. The procedure used for whole blood was that 
described by Brecher, Schneiderman, and Cronkhite (1953). With 
samples of platelet-poor plasma prepared from citrated blood, counts
t
A -1
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Fig. 2. Thrombelastograms of platelet-poor plasma from hemophilic dog (A-1) and normal dog (V-l).
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were made without further dilution, and the appropriate factor used . 
in calculating number of platelets per mm ,
Special reagents. Owren1s modified barbital buffer, pH 7.35, 
ionic strength of 0.154: 0.1N HCl, 43.0 ml; sodium veronal (diethyl- 
barbital), 1.175 g; NaCl, 1.467 g; deionized water, to 200 ml (Owren, 
1947). I
Gelatin-barbital buffer. 0.25%: 0.25 g gelatin (175 Bloom,
General Biochemicals) per 100 ml Owren1s modified barbital buffer; 
stored at 4° C.
Streptokinase (Varidase, Lederle). Stock solutions were prepared 
by diluting 1 vial of SK (20,000 units) with gelatin-barbital buffer 
to concentrations of either 1,000 or 2,000 units/ml. The solution 
was sub-divided into 0.1 ml volumes and stored at -20° C. For each 
run a new vial was used, in some cases further dilutions being 
required.
Choline dihydrogen citrate (Eli Lilly and Co.). 600 mg tablets,
No. 1697.
i
Epsilon-amino-caproic-acid (Sigma Chemical Co.). EACA dosage 
prepared by placing proper amount of crystals in gelatine capsule.
Plasma euglobulin fraction (human) for use with streptokinase. 
Lyophilized human plasma ("Anti-Hemophilic Plasma", Hyland Labora­
tories, Lot 260A168) was subdivided into 90-mg aliquots, equivalent 
to 1 ml original plasma plus the citrate used as anticoagulant. 
Weighings were made directly into small vials suitable for storage at 
-20° C and for reconstitution. Freshly separated euglobulins from 
these vials were prepared in the usual manner (see below) after
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adjustment of the diluted plasma to pH 5.4. After centrifugation, 
the euglobulins were reconstituted to 1/5 original volume of plasma 
with gelatin-barbital buffer. Beginning with System 5, a more 
efficient method was employed, and a higher pH (5.9) for the 
precipitation step was used. This second lot of the Hyland material 
(Lot 260X25), equivalent to 82 ml original plasma, was reconstituted 
after precipitation and centrifugation in 4.2 ml gelatin-barbital 
buffer, divided into 0.1 ml aliquots, lyophilized and stored at -20° C. 
For use as a component in an SK-containing mixture for thrombelasto­
graphy, the contents of a single vial were dissolved in 100 ;il 
deionized water and kept in an ice bath. Desired volumes were 
transferred to the TE cuvettes as needed.
Euglobulin clot lysis times. Platelet-poor citrated plasma,
0.5 ml, was diluted 1:19 with cold deionized water, 9.5 ml, ;'(4a. C).
The pH of the diluted plasma was brought to 5.4 by addition of 1% 
acetic acid. The plasma was stored for 15 min at 4° C and then 
centrifuged for 10 min at 3,000 rpm (1,500 g). The precipitate was 
reconstituted to original volume of citrated plasma with Owren's 
modified buffer, pH 7.35. The solution was clotted by addition of 
50 pi of 1.25% CaCl2 » The clotted euglobulins were put in a water 
bath of 37° C and observed every 5 min until the clot was totally 
lysed. The time necessary for dissolving of the clot was recorded.
Preparation of clotting-lysis mixtures for study by thromb- 
elastography. Five different systems were used. For those containing 
human plasma, the procedure was the following: Into a prewarmed
test tube (10 x 75 mm) kept in a 37° C water bath, desired volumes
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of the components were added in rapid succession: 2 volumes of
platelet-poor citrated dog plasma; 1 volume of reconstituted human 
plasma (Ortho-Diagnostic); 0.1 volume of SK-mixture; and 0.3 volume 
of 1.29% CaCl2 solution (warmed). A timer was started upon addition 
of the calcium chloride. The test tube was inverted several times for 
mixing of its contents. Immediately after, 0.35 ml of the mixture 
was transferred to the temperature-equilibrated TE cuvette, the 
appropriate pin was lowered, and the surface of the sample covered 
with oil. When the timer read 60 sec, the light for that cell was 
turned on.
Composition of the 3 mixtures containing human plasma differed 
in only one important respect: namely, concentration of SK in the 
system. These concentrations were 14.7, 38.5, and 29.1 SK units/ml 
final mixture in Systems 1, 2, and 3, respectively. Volumes of the 
several components used in System 1 were the following: 0.40 ml dog
plasma, 0.20 ml human plasma, 20 pi SK-mixture containing 10 units SK; 
60 pi CaCl2 solution. Systems 2 and 3 were prepared with volumes of 
components proportional to those given above, but total volumes were 
reduced slightly.
With mixtures containing human euglobulins (Systems 4 and 5), 
the following procedure was used. Into the thrombelastograph cuvette 
(37° C), the components other than calcium chloride were added in 
rapid succession. A stop watch was started upon transfer of the first 
component, 0.25 ml platelet-poor dog plasma; addition of 25 pi each 
of a human euglobulin preparation and of a diluted SK-mixture followed. 
At precisely 2 min after transfer of the dog plasma, 50 pi CaCl2
(1.29%) was added, and the pin lowered and raised 3 times for mixing. 
The pin was lowered once more, and the surface of the liquid covered 
with oil. At 3 min after the starting of the stop watch, the light 
switch for the cuvette was turned on.
As indicated previously, 2 different preparations of euglobulins 
were used. Also, relative concentrations of the euglobulins in the 
clotting-lysis mixtures differed. Thus, in System 5, the second lot 
of euglobulins (precipitated at pH 5.9) was used in a concentration 
4 times that of the first lot with System 4 (precipitated at pH 5.4). 
Concentrations of SK in the 2 systems differed slightly —  in System 
4, final SK concentration was 6.5 units/ml; in System 5, 6.8 units/ml. 
Rapid lysis of the clots with such low concentration of SK is 
explained in large measure by the reduction in concentration of 
inhibitors of fibrinolysis in preparing the euglobulins from the 
human plasma used. Before making decisions concerning concentrations 
of iJK to be routinely used in System 4 and in System 5, correlation 
cuv-ves were constructed from data on fibrinolysis times of mixtures 
using a given sample of dog plasma and varying concentrations of SK 
(Fig. 3 for correlation curve on V-l, using first euglobulin 
preparation). '
Thrombelastographic analysis of SK-activated fibrinolysis of dog 
plasma. A thrombelastogram of SK-activated fibrinolysis of platelet- 
poor citrated dog plasma is represented in Fig. 4* Fibrinolysis time, 
beginning from the time of clotting to complete lysis, was measured 
in millimeters from the end of the reaction time, r, to a point, f, 
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Fig. 3. Correlation curve relating SK concentration and 
fibrinolysis times. Data were obtained on tests 





Fig. 4. Thrombelastogram illustrating’ SK-activated fibrinolysis. 
The clot-lysis mixture contained platelet-poor plasma 
from an adult hemophilic dog (G-3), a human euglobulin 
fraction, CaCl2 » and streptokinase. On diagram:, 
r, reaction time; k, clot formation time; ma, maximum 
amplitude; f, end of fibrinolysis.
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lysis of the clot. Since the film moved at 2 mm/min while being 
exposed in the thrombelastograph, the above measurement was divided
f
by 2 to convert the fibrinolysis time measured in millimeters to 
fibrinolysis time expressed in minutes.
The maximum amplitude, a representation of clot firmness, is the 
greatest distance in millimeters between the two branches of the 
thrombelastogram. The maximum amplitude for normal platelet-poor 
citrated human plasma is considered to be 20 mm. Arbitrarily, 20 mm 
was chosen to be the end of k, clot formation time (deNicola, 1957).
Statistical Analysis. An analysis of variance was used to test 
statistically the effect of choline on fibrinolysis in the dog.
The general least squares procedure was used in order to remove the 
effects due to disproportionate sub-class numbers as well as to remove 
the effects due to the co-variables, the day of choline administration 
and the number of platelets in the plasma. The variables subjected 
to this analysis were differences in control and choline test period 
fibrinolysis times and in control and choline test period maximum 
amplitudes. To obtain observations as measured for the above 
variables, values for the control period were averaged, and this 
average subtracted from the corresponding observed value for each 
day of choline treatment. In using the following model for 
determining population, all the estimates were independent. The 
model for the analysis of variance is as follows:
Yijkl = >  + si + Dij + pk + 0  1 <xi jkl “ *) +




Y^jki is observation as measured
p  is mean of observations as measured
is effect of "i" status (hemophilic or normal)
Dij is effect of "j" (individual) dog within "i" status
is effect of "kM system of 5 systems used
fix is partial linear regression coefficient
xijkl *s day of "I” observation on "k" procedure of
"j" dog in "i" status 
x is mean day of observation
^ 2  is partial quadratic regression coefficient
fi 3 is partial cubic regression coefficient
£  ijkl ds random error due to all variables not accounted 
for previously
To test for statistically significant differences due to the 
status of the dog, the day of choline treatment, and the procedure 
used, F values were calculated from the above estimates (F = variance 
ratio).
To test for statistically significant differences due to the effect
of choline on fibrinolysis times and maximum amplitudes, t values were
calculated (t = least squares mean ).
standard error
In all cases of statistical analysis, statistical significance 
was considered only at the 1% level of probability.
RESULTS
Major characteristics of thrombelastograms obtained with 
plasma from dogs during the control periods; influence of SK 
concentration and of the form In which human proactivator supplied. 
With mixtures containing human plasma as source of proactivator, 
influence of SK concentration was conspicuous.in shifting 
fibrinolysis times. Plasma samples from 2 dogs (V-l and G-4) 
were tested with each of the 3 concentrations of SK. Plotting 
of log fibrinolysis time versus log concentrations of SK produces 
essentially a straight line (Fig. 5), as was found by Astrup
(1965) using purified reagents. Mean fibrinolysis times for 
dog V-l obtained with mixtures containing 14.7, 38.5, and 29.1 
SK units/ml (Systems 1, 2, and 3) were 133, 12, and 51 min, res­
pectively. For dog G-4, comparable values were 183, 25, and 73 min, 
respectively (Table 1). For both dogs, the maximum amplitudes 
developed with the lowest and the intermediate concentrations of SK 
were considered satisfactory; with 38.5 units/ml (System 2), however, 
maximum amplitudes were sometimes less than 20 mm (Table 2) . Data 
obtained on dogs G-3, K-l, K-2, and K-3 with Systems 2 and 3 
followed the trends described for V-l and G-4. Clots prepared with 
plasma from the young dogs (K-l, K-2, K-3) lysed somewhat faster than 
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Log (SK]
Fig. 5. Relation between SK concentration and fibrinolysis times. Data were
obtained on tests with plasma from adult normal dog (V-l), using human 
plasma as proactivator. Influence of choline on SK activity is 
exhibited by shift in position of the curve.
roro
Table 1. Fibrinolysis times for dogs during control period, choline treatment, and after choline
treatment. Values given are means for the number of observations indicated in parentheses. 
Times for the period after treatment are for samples collected 5 or more days after 
discontinuance of choline.
Fibrinolysis Times (minutes)
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*Statistically significant at 1% level.
Table 2. Maximum amplitudes for dogs during control period, choline treatment, and after choline
treatment. Values given are means for the number of observations indicated in parentheses. 




G-4d* V-lc? G-32 K-lcf K-2c? K-3cT A-Id*
Control 37(6). 31(7) • • • • • • • • • • • • • • • •
1 300 mg/dose Choline 32(6) 30(6) • • • • • • • • • • • • • • • •
After 32(3) 33(4) • • • • • # • • • • • • • • • •
Control 23(3) 21(4) 26(1) 16(3) 16(3) 17(3)
2 600 mg/dose Choline* 27(3) 24(3) 34(3) 24(2) 20 (2) 20 (2)
After 20(3) 19(2) 25(2) 23(3) 19(3) 22(3)
Control 32(3) 21(3) 33(1) 22(2) 19(3) 20(3)
3 600 mg/dose Choline 30(3) 27(3) 37(3) 28(2) 26(2) 27(2)
After 28(2) 27(2) 37(2) 28(3) 25(3) 29(3)
Control 15(2) • • • o 8(1) 12(1) 11(1) 11(1) 11(2)
4 300 mg/dose Choline* 21(3) • • • • 15(3) 23(2) 20(2) 17(2) 16(3)
After 11(1) • • • • 10(1) 17(1) 14(1) 9(1) 5(1)
Control 34(3) • • • • 27(3) 35(3) 33(3) 34(3) 29(3)
5a 300 mg/dose Choline* 47(5) • • • • 47(5) 52(5) 44(5) 35(5) 38(5)
After 34(2) • • • • 35(2) 31(2) 26(2) 35(2) 35(2)
Control 34(2) • • • • • • • • 31(2) 26(2) 35(2) 35(2)
5b 600 mg/dose Choline* 38(3) • • • • • •• . 36(2) 28(2) ...37(2) 32(2)
*Statistically significant at 1% level.
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from V-l (normal adult dog) lysed more rapidly than did those with 
plasma from G-3 or G-4 (hemophilic adult dogs), but whether 
characteristic differences in fibrinolysis times between adult normal 
and hemophilic dogs of this colony occur cannot be determined from 
the 3 dogs tested. There was no significant difference between 
hemophilic and normal dog fibrinolysis times and maximum amplitudes 
as measured in all 5 systems tested (Table 4).
With the concentration of SK chosen for use with the first 
euglobulin preparation (System 4), lysis times ranged from 1 0 - 2 5  
min in the 6 dogs tested (G-3, G-4, A-l, K-l, K-2, K-3). Maximum 
amplitudes were rather low (8-15 mm).
With clot-lysis mixtures designated as System 5 (containing 
the second euglobulin preparation in relatively high concentration), 
SK was used at almost the same concentration as in the preceding 
series. Average maximum amplitudes attained in thrombelastograms 
of the 6 dogs tested ranged from 27 - 34 mm, more than twice those 
shown with System 4. Fibrinolysis times were also increased, 
average values ranging from 25 - 54 minutes.
Effect of choline on thrombelastograms. Statistical analysis 
combining all 5 test systems showed that choline administration 
significantly increased fibrinolysis times and maximum amplitudes 
as measured (Table 3). Only Systems 2 and 4 did not demonstrate a 
significant increase in fibrinolysis times even though the mean 
fibrinolysis times were more than or almost doubled in every case. 
This lack of statistical significance may be because the fibrino­
lysis times of Systems 2 and 4 were shorter in general than those
Table 3. Statistical analysis of differences in fibrinolysis times and
maximum amplitudes between control and choline periods. Analysis 



















106 4.23 1.11 3.81*
*Statistically significant at 1% level.
Table 4. Analysis of variance on data for fibrinolysis times and maximum amplitudes, testing 






















1 126366 126366 2.60
Control Between Procedures 4 1424449 356112 21.89*
Maximum Amplitude: Between Status
Choline (Hemophilic or normal) 
minus
1 17.8 17.8 0.186
control Between Procedures 4 1025.7 256.4 5.68*
*Statistically significant at 1% level.
of the other systems, resulting in a smaller least squares mean 
while still having approximately the same standard error. Table 1 
illustrates the mean fibrinolysis times and those times for choline 
periods found significantly different from control periods. In 
System 2, the maximum amplitudes are significantly increased, while 
Systems 1 and 3 do not demonstrate this effect. Maximum amplitudes 
during choline treatment are 20 mm or more in almost every case 
(Table 2).
In the first euglobulin mixture (System 4, 6.5 SK units/ml), 
mean fibrinolysis times range from 36-81 min in the same dogs 
previously tested without choline treatment (Table 1). Mean 
maximum amplitudes are all significantly increased into a range of 
15-23 mm (Table 2).
System 5 (euglobulin mixture containing 6.8 SK units/ml) 
p'roduced mean fibrinolysis times of dogs on choline treatment 
ranging from 88-159 min, and mean maximum amplitudes of 35-52 mm. 
Fibrinolysis times and maximum amplitudes are both significantly 
increased (Tables 1 and 2).
Thrombelastograms after discontinuance of choline. With 
samples collected 5 days or more after choline treatment, fibrino­
lysis times and maximum amplitudes for the majority of the dogs 
were in the range noted before choline treatment. System 1 produced 
a mean fibrinolysis time of 172 min and a mean maximum amplitude of 
32 for G-4; for dog V-l, 117 min and 33 mm. Systems 2 and 3 provide 
data which follows the trends described for dogs G-4 and V-l
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(Tables 1 and 2). Fibrinolysis times of those samples collected 
5 days or longer after choline treatment decreased significantly 
from those times measured during choline treatment. No 
significant decrease in maximum amplitudes in the plasmas collected 
5 days or longer after cessation of choline was observed.
In System 4 the mean fibrinolysis times for all the dogs tested 
ranged from 7 - 1 4  min, slightly lower than the range found before 
choline treatment but not significantly lower than during choline 
treatment. Mean maximum amplitudes range from 5 - 1 7  mm, lower 
than during choline treatment but not significantly so.
Mean fibrinolysis times in System 5 after choline treatment 
range from 21 - 35 mm. These values represent a significant 
decrease from those obtained when the dogs were on choline. There 
are no statistically significant differences between the "before" 
and "after" fibrinolysis times and maximum amplitudes in any of the 
experiments.
Effect of platelet numbers. Although the dog platelet-poor 
plasma samples contained varying numbers of platelets, no effect 
of platelet numbers could be correlated with fibrinolysis times.
A negative linear regression coefficient (-0.6057), relating 
differences between control and test period maximum amplitudes 
with platelet numbers, supported the correlation that as platelet 
numbers in the plasma sample increased, the differences between 
control and test period maximum amplitudes decreased.
Comparison of fibrinolysis times for choline administered at 
five times the normal dietary level and ten times the normal dietary
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level. In addition to 1 period in which 6 dogs were given 5 times 
the normal dietary level of choline, 5 of the dogs were given twice 
that amount of choline while using the same system, System 5. 
Differences for the fibrinolysis times between the 2 treatments are 
not significant.
Effect of system used. Significant differences between both 
the fibrinolysis times and maximum amplitudes recorded in the various 
systems used were found (Table 4). That is to say, the testing 
system can be adjusted to provide data within desired ranges of 
measurement.
Effect of citric acid. Citric acid in amounts equivalent 
to the citrate in choline citrate at 10 times the normal dietary 
level of choline was given to 6 dogs (G-3, G-4, K-l, K-2, K-3, V-l) 
to test the effect of citrate ions on fibrinolysis times. Using 
Systems 2 and 3, an increase in fibrinolysis times was not observed. 
With System 2, the mean fibrinolysis time for the 6 dogs during 
control period was 20 min with a standard deviation of * 6; for 
citric acid test period, 16 i 5 min. With System 3, the mean 
fibrinolysis time for the control period was 72 + 21 min; for 
Citric acid test period, 50 "t 12 min. One-half of the above dose 
of citric acid was given to 3 dogs (A-l, K-l, K-2). The mean 
fibrinolysis time, using System 5, was 24 * 7 min for the control 
period; 22 1" 7 min for the citric acid test period.
Of 15 observations made during citric acid treatment, an 
increase in fibrinolysis time occurred in 1 case, in another there
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was no change, and in the remaining 13, the fibrinolysis times 
were less than during the control period.
Effect of choline treatment of euglobulin clot lysis times.
To supplement the information gathered on fibrinolysis times with 
the thrombelastograph, euglobulin clot lysis times were measured 
with some of the plasmas obtained for use on the thrombelastograph 
while using System 5. This supplementary information was obtained 
in order to have an additional measure of fibrinolytic activity or 
experimental inhibition of it.
Six dogs (G-4, G-3, A-l, K-l, K-2, K-3) administered choline 
at 5 times the normal dietary level had a mean euglobulin clot lysis
t._rtime of 83 min with a standard deviation of T 11. The mean
euglobulin clot lysis time for samples collected 5 days or more
+after stoppage of choline administration was 29 _ 8 min. Five 
dogs (G-4, AtI, K-l, K-2, K-3) were then given choline at twice 
the above dosage and had a mean euglobulin clot lysis time of 
35 i 4 min, as compared to a control period mean of 28 I- 3 min.
Euglobulin clot lysis times were significantly increased by 
choline in both of the above experiments.
Influence of EACA on thrombelastographic patterns. One dose 
of EACA, 0.34 mg/kg, was given to 2 normal dogs. Using System 5, 
fibrinolysis times during a non-treatment period for adult normal 
dog V-l and young normal K-9 were 18 and 33 min, respectively.
Three hours after 1 peroral dose of EACA, fibrinolysis times 
increased to 190 min for dog V-l and 300 min for dog K-9. Seven 
hours after another dose 5 days later, the times were much shorter —  
V-l, 60 min; K-9, 110 min. The following day, the times were even
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lower, approaching the non-treatment values. Maximum amplitudes 
were increased after the 3-hour dose and lessened during the 
following observations described above.
Epsilon - aminocaproic acid had great inhibition on 
fibrinolysis in vivo a short time after ingestion and absorption. 
Fibrinolytic inhibition by EACA diminishes markedly after 3 hours 
(Niewiarowski and Wolosowicz, 1966).
DISCUSSION
It is yet to be demonstrated without question that hemophilic 
bleeding can be partially controlled with perorally administered 
drugs which do not alter the clotting mechanisms. But the 
theoretical basis for such is at hand, and is supported by the 
studies here reported. The theory of Astrup et al. (I960) suggests • 
that while there is a dynamic balance between continuous fibrin 
formation and fibrinolysis in normal people, in hemophilia the 
balance is upset by retarded fibrin formation while fibrinolysis 
is essentially normal but possibly acting on the slowly formed 
fibrin to prevent proper hemostasis. Therefore, hemophilic bleeding 
might be partially controlled by prolonging fibrinolysis, thus 
partially restoring the dynamic hemostatic balance.
Choline, shown to be a major ingredient of peanut extracts 
which shorten bleeding time, is here revealed as a substance which 
can delay fibrinolysis, both as measured by the euglobulin clot 
lysis method, and as measured by thrombelastographic recording of 
streptokinase-activated fibrinolysis of plasma clots. A possible 
benefit to hemophiliacs of prolonged fibrinolysis is more than 
retention of a slow-forming clot: Retardation of fibrinolysis is
important to enable the clot to form in the first place. When 
fibrinolysis was quickly activated with SK mixtures in this study,
33
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even normal dog blood failed to clot enough to enlarge the 
thrombelastogram. With the SK mixtures, it was necessary to cause 
the hemophilic dog blood to clot before full activation of fibrino­
lysis. Otherwise, the mixture exhibited no clotting on the 
thrombelastograms. It seems that as clotting began, the incipient 
clot was unable to form because of concurrent fibrinolysis. Support 
for this idea comes from observations that thrombelastograms of a 
sample of dog plasma without SK always indicated a more elastic clot 
(higher maximum amplitudes) than did a substitute sample of the same 
plasma treated with SK. The slightly lowered elasticity of the 
latter could be the result of slight early initiation of some 
fibrinolysis while clotting was proceeding.
Streptokinase-activated fibrinolysis parallels natural activa­
tion of fibrinolysis in the body in that the SK-proactivator 
complex activates plasminogen, converting it into plasmin. One may 
compare this type fibrinolysis with that initiated by adding plasmin 
directly to the system. In the latter case, the maintenance of a 
maximum amplitude on the thrombelastogram would not occur. The 
thrombelastographic patterns produced by plasmin and activators of 
plasminogen are distinctly different (Astrup and Egeblad, 1965).
There is slight evidence that choline treatment may indeed be 
hemostatic in hemophilic dogs. During 2 choline treatment periods 
the toenails of the adult male bleeder (G-4) were clipped closely 
to induce bleeding. The bleeding from toenails stopped permanently 
in less than 3 hours in both cases. The immature male bleeder (A-l) 
had his toenails clipped similarly but was not under choline
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treatment in one case. His toenails bled for 10 hours before 
choline was finally administered late at night and the bleeding was 
stopped by the next morning. At another time though, when under 
choline treatment, this young dog did bleed intermittently from 
a clipped toenail for 24 hours. However, he was very active and 
the bleeding was more a rebleeding through disturbance of the 
wound. Before choline treatment, his fibrinolysis times were rather 
short; under treatment they became about as long as the normal times 
of the other dogs. On another occasion this dog had a large 
ecchymosis or hematoma which was progressively getting larger in 
his neck where a venipuncture had been performed. He was then 
treated with choline and after 1 day the enlargement seemed to 
stop, and after 3 days the blue coloration had disappeared and there 
was a hard thrombus where the bleeding had occurred. In another 
case, dog G-4, was observed to be bleeding as evidenced by the 
presence of blood in his feces and by a low hematocrit. Fibrino­
lysis times indicated enhanced fibrinolytic activity (Fig. 6). He 
was treated with choline and 3 days later his fibrinolysis times 
were greatly increased, indicating decreased fibrinolytic activity. 
His feces were also observed to appear normal. Eight days after 
the last dose of choline, fibrinolysis times had returned to a 
normal range, although never as short as they had been during the 
bleeding period. These observations, while not proving the 







Fig. 6. Thrombelastograms demonstrating effects of choline and of SK concentration on
fibrinolysis. Patterns are for adult hemophilic dog (G-4), using human euglobulin 
fraction as source of proactivator and of clotting factors. In each of the three 
groups, the top recording is for the highest SK concentration. A. Five hours before 
choline. At this time dog had blood in feces and low hematocrit. Fibrinolysis time 
shorter than usual control valves. B. After 3 days of choline treatment. C. Eight 




While the above discussion may imply that choline treatment 
might relieve difficult cases of bleeding, any beneficial effect 
of choline may be overridden by increased fibrinolytic action 
caused by stress, such as excessive loss of blood, repeated blood 
sampling, trauma, strenuous exercise, and even possibly excessive 
alcoholic consumption. Fearnley, Ferguson, Chakrabarti, and 
Vincent (1960) reported increased fibrinolytic activity of blood 
after beer consumption. During the early phase of one period of 
choline administration, my test dogs were bled daily, and larger 
than usual volumes were taken. This period was not included in 
the results because the daily sampling caused a rapid decrease in 
fibrinolysis times. The same dogs were continued on choline 
treatment without interruption and subsequently they were bled 
every other day. The clot lysis times during this second period 
significantly became prolonged (this was System 5, reported above). 
Celander and Celander (1968) report increased fibrinolytic activity 
in dogs resulting from daily bleedings.
Another implication that might arise is that excessive 
choline consumption in normal subjects may result in depression 
of fibrinolysis so that interference with resolution of thrombotic 
deposits in the vascular system may occur. This interference 
could possibly manifest itself in resultant pathology of the cardio 
vascular system.
This study is a first attempt at studying fibrinolysis of 
hemophilic blood using thrombelastography. It was necessary to 
modify techniques previously used. The first problem was the
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formation of a satisfactory clot before clot lysis occurred.
Thrombin was not useful because a satisfactory maximum amplitude 
could not be obtained. My choice of the several activators of 
fibrinolysis was streptokinase. Urokinase proved to be 
unsatisfactory using whole blood because clot lysis was not uniform 
and high levels of urokinase were needed. With streptokinase, it 
was necessary to use a human source of proactivator. Human 
diagnostic plasma provided proactivator and clotting factors for 
hemophilic plasma but contained some undesirable factors (e.g., 
inhibitors of fibrinolysis). Some advantage was gained by 
selecting human euglobulins as a source of proactivator and of 
clotting factors for hemophilic plasma. Much less SK was needed 
with the euglobulins (Systems 4 and 5).
This study employed platelet-poor dog plasma because the 
platelet-rich clots in the thrombelastograph produced large 
maximum amplitudes, and lysed irregularly, in that the clots would 
break away from walls of the cuvettes. A level of platelets of 
3000/mm^ or so produced satisfactory clots that lysed smoothly.
A higher platelet level of 10000 to 20000/mm^ is undesirable in 
that it tends to mask the higher maximum amplitude values of choline 
treated anima'ls. These higher maximum amplitudes are interpreted 
to signify that choline treatment delays fibrinolysis in the test 
system long enough for the maximum amplitude to be reached.
Since choline was used in the citrate form, it was necessary • 
to explore the effect of the citrate alone on fibrinolysis.
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Although the results seemed to indicate no statistical difference 
in fibrinolysis times between untreated and citrate-treated dogs, 
the times with citrate were shorter. There may be a high dosage 
level at which the citrate may interfere with the choline effect.
It appears that choline prolongs fibrinolysis only after it 
has been metabolized. Though the choline delayed fibrinolysis 
times, the delay appeared within 24 hours, but the effect did not 
manifest itself as quickly as did the effect of EACA, which was 
evidenced 3 hours after administration. The action of EACA is as 
a direct inhibition of plasminogen activation (Alkjaersig, Fletcher, 
and Sherry, 1959; Ablondi, Hagan, Philips and DeRenzo, 1959). 
Choline, like EACA, also seems to mediate inhibition of plasminogen 
activation. In thrombelastographic analysis, persistence of a 
constant maximum amplitude for a short while before visible lysis 
' is evidence that plasminogen activation is delayed (Astrup and 
Egeblad, 1965). Also, a shift in the curve in the log plot of 
fibrinolysis time vs. SK concentration indicates that a constant 
percentage of SK is rendered ineffective by choline, suggesting that 
inhibition of fibrinolysis is acting at the plasminogen activation 
level. Although it seems that choline may be inhibiting the 
activation of plasminogen, the mechanism is unknown.
Figure 7 illustrates the difference between thrombelastograms 
of SK-activated clot lysis and of lack of lysis of dog plasma clot 
and the effect of plasmin activity on maximum amplitude. The 













of the clot which lyses. The difference in maximum amplitudes is 
a measure of the activity of plasmin, as shown below the zero line. 
The activity of plasmin occurs after plasminogen activation. A 
small initial activation probably occurs, followed by an increasing 
later activation which causes the clot to lyse more rapidly.
Although choline is acting as an antagonist to SK-activated 
fibrinolysis, observations on the bleeding episodes of the dogs 
mentioned previously and the prolonged euglobulin clot lysis times 
indicate that the choline effect is not restricted to inhibition of 
SK-activated fibrinolysis.
An understanding of the action of choline in fibrinolysis 
will likely come when it is known through which of the roles the 
effect is mediated: 1) methyl donor; 2) lipotropic agent;
3) precursor to phosphatidyl ethanolamine, which is a known 
' inhibitor of fibrinolysis (Reid et al., 1965), or 4) any of the 
other roles choline may play in metabolism.
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